Does Cosentyx Dose Affect Side Effect Frequency?
Higher doses of Cosentyx (secukinumab) show a dose-dependent increase in certain side effects, particularly upper respiratory tract infections, based on clinical trial data. In phase 3 trials for plaque psoriasis, infections occurred in 46-51% of patients on 300 mg doses versus 43% on 150 mg, with upper respiratory infections rising from 25% at 150 mg to 29% at 300 mg.[1][2]
Which Side Effects Increase Most at Higher Doses?
- Infections: Upper respiratory infections are most notably higher (e.g., 29% at 300 mg vs. 25% at 150 mg in psoriasis trials). Oral herpes and tinea infections also edge up slightly.[1]
- Diarrhea and inflammatory bowel disease: More frequent at 300 mg (4-5%) than 150 mg (2-3%) in psoriasis studies; Crohn's disease flares reported in 1-2% of higher-dose patients with history.[2][3]
No clear dose-response for serious infections, injection-site reactions (7-11% across doses), or candidiasis (3-4%).[1]
How Do Doses Compare Across Conditions?
| Condition | Common Doses | Key Dose-Related Side Effects |
|-----------|--------------|-------------------------------|
| Plaque Psoriasis | 150 mg or 300 mg | Higher infection rates at 300 mg[1] |
| Psoriatic Arthritis | 150-300 mg | Similar pattern, but less pronounced[2] |
| Ankylosing Spondylitis | 150-300 mg (with loading) | Diarrhea up to 5% at higher doses[3] |
| Hidradenitis Suppurativa | 300 mg | Infections in 48%, no lower-dose comparator yet[4] |
Loading doses (e.g., weekly initial injections) temporarily elevate risks across all.[2]
What Do Long-Term Data and Labels Say?
Prescribing information notes infections as most common overall (47%), without strong dose stratification, but pooled safety data confirm modest increases at 300 mg.[1][5] Five-year extension trials report stable rates, with no new dose signals.[3] No patents directly cover dosing-side effect links; Cosentyx patents expire 2033-2034 in major markets.[6]
Patient Reports and Real-World Risks
User forums and FAERS database show anecdotal higher infection complaints at 300 mg, especially in winter. Risk factors amplifying dose effects: age >65, diabetes, or immunosuppression (odds ratio ~1.5 for infections).[7] Monitor for IBD history—discontinuation advised if flares occur.
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: Langley RG et al., N Engl J Med 2014 (ERASURE/SCULPTURE trials)
[3]: Baeten D et al., Ann Rheum Dis 2018 (MEASURE trials)
[4]: FDA Approval Summary, Hidradenitis 2023
[5]: Drugs.com Cosentyx Side Effects
[6]: DrugPatentWatch.com - Secukinumab Patents
[7]: FAERS Analysis via OpenFDA, 2023